News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,140 Results
Type
Article (5017)
Company Profile (17)
Press Release (220106)
Section
Business (82205)
Career Advice (461)
Deals (15042)
Drug Delivery (8)
Drug Development (19063)
Employer Resources (30)
FDA (3677)
Job Trends (3901)
News (120108)
Policy (7503)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (292)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14773)
ALS (20)
Alzheimer's disease (248)
Antibody-drug conjugate (ADC) (11)
Approvals (3694)
Artificial intelligence (41)
Autoimmune disease (3)
Automation (3)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (9)
Brain cancer (7)
Breast cancer (48)
Cancer (444)
Cardiovascular disease (22)
Career advice (393)
Career pathing (3)
CAR-T (31)
Cell therapy (102)
Cervical cancer (2)
Clinical research (16026)
Collaboration (167)
Compensation (168)
Complete response letters (2)
COVID-19 (302)
CRISPR (7)
C-suite (104)
Cystic fibrosis (16)
Data (510)
Depression (5)
Diabetes (42)
Diagnostics (2041)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (40807)
Editorial (2)
Employer branding (6)
Employer resources (31)
Events (37751)
Executive appointments (311)
FDA (3926)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (184)
Gene editing (15)
Generative AI (2)
Gene therapy (50)
GLP-1 (108)
Government (412)
Guidances (16)
Healthcare (5037)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (13)
Indications (6)
Infectious disease (318)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7822)
IRA (3)
Job creations (1121)
Job search strategy (360)
Kidney cancer (7)
Labor market (5)
Layoffs (100)
Leadership (5)
Legal (2332)
Liver cancer (17)
Lung cancer (54)
Lymphoma (31)
Management (10)
Manufacturing (49)
MASH (27)
Medical device (3859)
Medtech (3860)
Mergers & acquisitions (7425)
Metabolic disorders (121)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (1)
Neuroscience (340)
NextGen: Class of 2025 (1674)
Non-profit (727)
Northern California (921)
Now hiring (3)
Obesity (53)
Opinion (30)
Ovarian cancer (17)
Pain (12)
Pancreatic cancer (14)
Parkinson's disease (26)
Partnered (4)
Patents (21)
Patient recruitment (29)
Peanut (5)
People (24589)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4776)
Phase II (6961)
Phase III (5548)
Pipeline (548)
Policy (9)
Postmarket research (625)
Preclinical (1869)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (67)
Real estate (1874)
Recruiting (8)
Regulatory (5113)
Reports (14)
Research institute (301)
Resumes & cover letters (68)
Rett syndrome (3)
Schizophrenia (21)
Series A (27)
Series B (23)
Sickle cell disease (7)
Southern California (696)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (4)
Startups (1008)
Stomach cancer (1)
Supply chain (10)
Tariffs (4)
United States (6997)
Vaccines (36)
Venture capitalists (2)
Weight loss (21)
Women's health (1)
Date
Today (49)
Last 7 days (137)
Last 30 days (743)
Last 365 days (10022)
2025 (2950)
2024 (11027)
2023 (13193)
2022 (18659)
2021 (19679)
2020 (18240)
2019 (13205)
2018 (10205)
2017 (10002)
2016 (9157)
2015 (12118)
2014 (9588)
2013 (7708)
2012 (8331)
2011 (8796)
2010 (8635)
Location
Africa (184)
Alabama (13)
Alaska (2)
Arizona (59)
Arkansas (1)
Asia (11451)
Australia (1608)
California (1931)
Canada (696)
China (71)
Colorado (82)
Connecticut (91)
Delaware (29)
Europe (24504)
Florida (269)
Georgia (33)
Idaho (23)
Illinois (112)
India (6)
Indiana (64)
Iowa (1)
Japan (71)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (40)
Maryland (220)
Massachusetts (1545)
Michigan (85)
Minnesota (139)
Mississippi (1)
Missouri (22)
Montana (16)
Nebraska (12)
Nevada (23)
New Hampshire (15)
New Jersey (557)
New Mexico (5)
New York (469)
North Carolina (326)
North Dakota (2)
Northern California (921)
Ohio (56)
Oklahoma (5)
Oregon (4)
Pennsylvania (342)
Puerto Rico (1)
Rhode Island (13)
South America (276)
South Carolina (5)
Southern California (696)
Tennessee (40)
Texas (227)
Utah (59)
Virginia (46)
Washington D.C. (9)
Washington State (174)
West Virginia (2)
Wisconsin (22)
225,140 Results for "durect corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DURECT Corporation announced financial results for the three months ended March 31, 2024 and provided a business update.
May 13, 2024
·
11 min read
FDA
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).
May 21, 2024
·
9 min read
Business
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation, a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, announced that the company will report its first quarter financial results on Monday, May 13, 2024.
May 7, 2024
·
4 min read
Business
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DURECT Corporation announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
March 27, 2024
·
12 min read
Business
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
DURECT Corporation announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024.
March 20, 2024
·
4 min read
Drug Development
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DURECT Corporation announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver Congress 2024 to take place June 5-8, 2024 in Milan, Italy.
April 30, 2024
·
7 min read
Biotech Bay
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
DURECT Corporation announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024.
February 7, 2024
·
4 min read
Business
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
DURECT Corporation announced financial results for the three months ended September 30, 2023 and provided a corporate update.
November 13, 2023
·
13 min read
Business
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
DURECT Corporation announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023.
November 9, 2023
·
4 min read
Biotech Bay
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
DURECT Corporation, announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.
March 4, 2024
·
5 min read
1 of 22,514
Next
